NOVAVAX INC Business Finance Contracts & Agreements
99 Contracts & Agreements
- Exchange Agreements (13 contracts)
- Facility Agreements (1)
- Funding Agreements (2)
- Guaranty Agreements (1)
- Indenture Agreements (2)
- Investment Agreements (1)
- Investor Rights Agreements (1)
- Modification Agreements (25)
- Note Agreements (10)
- Pledge Agreements (2)
- Purchase Agreements (13)
- Registration Rights Agreements (2)
- Release Agreements (1)
- Security Agreements (2)
- Share Agreements (1)
- Stock Agreements (11)
- Subscription Agreements (4)
- Underwriting Agreements (6)
- Warrant Agreements (1)
- Securities Subscription Agreement, dated May 10, 2024, by and between Novavax, Inc. and Sanofi Pasteur Inc (Filed With SEC on May 13, 2024)
- Modification No. 21 to Undefinitized Project Agreement No. 1, dated February 6, 2024, between the Company and Advanced Technology International (Filed With SEC on May 10, 2024)
- Modification No. 20 to Undefinitized Project Agreement No. 1, dated December 1, 2023, between the Company and Advanced Technology International (Filed With SEC on May 10, 2024)
- Modification No. 19 to Undefinitized Project Agreement No. 1, dated September 19, 2023, between the Company and Advanced Technology International (Filed With SEC on May 10, 2024)
- Securities Subscription Agreement, dated as of August 8, 2023, between Novavax, Inc. and SK bioscience Co., Ltd (Filed With SEC on August 8, 2023)
- Form of Non-Statutory Stock Option Award Agreement (Filed With SEC on August 8, 2023)
- Amendment No. 4 to Advanced Purchase Agreement, dated as of July 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Filed With SEC on August 8, 2023)
- Amendment No. 3 to Advanced Purchase Agreement, dated as of April 5, 2023, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Filed With SEC on August 8, 2023)
- Amendment No. 2 to Advanced Purchase Agreement, dated as of April 6, 2022, between the Company and the Commonwealth of Australia as Represented by the Department of Health (Filed With SEC on August 8, 2023)
- Amendment No. 4 to Advanced Purchase Agreement, effective as of June 30, 2023, between the Company and His Majesty the King in Right of Canada, as represented by the Minister of... (Filed With SEC on August 8, 2023)
- Amendment No. 3 to Advanced Purchase Agreement, effective as of (Filed With SEC on August 8, 2023)
- Amendment No. 2 to Advanced Purchase Agreement, effective as of (Filed With SEC on August 8, 2023)
- Amendment No. 1 to Advanced Purchase Agreement, effective as of (Filed With SEC on August 8, 2023)
- Modification No. 18 to Undefinitized Project Agreement No. 1, dated May 25, 2023, between the Company and Advanced Technology International (Filed With SEC on August 8, 2023)
- Modification No. 17 to Undefinitized Project Agreement No. 1, dated February 6, 2023, between the Company and Advanced Technology International (Filed With SEC on May 9, 2023)
- Modification No. 03 to Base Agreement between the Company and Advanced Technology International, dated as of November 30, 2022 (Filed With SEC on February 28, 2023)
- Form of Restricted Stock Unit Award Agreement under the Novavax, Inc. 2023 Inducement Plan (Filed With SEC on January 9, 2023)
- Form of Non-Statutory Stock Option Agreement under the Novavax, Inc. 2023 Inducement Plan (Filed With SEC on January 9, 2023)
- Indenture, dated as of December 20, 2022, between Novavax, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (Filed With SEC on December 21, 2022)
- Underwriting Agreement, dated as of December 15, 2022, between Novavax, Inc. and J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the... (Filed With SEC on December 19, 2022)
- Modification No (Filed With SEC on November 9, 2022)
- Modification No (Filed With SEC on November 9, 2022)
- Modification No (Filed With SEC on November 9, 2022)
- Modification No. 02 to Base Agreement between the Company and Advanced Technology International, dated as of August 2, 2022 (Filed With SEC on November 9, 2022)
- Modification No. 01 to Base Agreement between Novavax, Inc. and Advanced Technology International, dated as of March 23, 2022 (Filed With SEC on May 10, 2022)
- Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International (Filed With SEC on March 1, 2022)
- Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2022)
- Amendment to Advance Purchase Agreement between the Company, and the Commonwealth of Australia as represented by the Department of Health, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
- Advance Purchase Agreement, dated August 16, 2021, between Novavax, Inc., Novavax CZ and the European Commission (Filed With SEC on November 5, 2021)
- Modification No. 11 to Undefinitized Project Agreement No. 1, dated August 26, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
- Modification No. 10 to Undefinitized Project Agreement No. 1, dated August 6, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
- Modification No. 09 to Undefinitized Project Agreement No. 1, dated July 16, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
- Modification No. 08 to Undefinitized Project Agreement No. 1, dated June 4, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on August 5, 2021)
- Modification No. 07 to Undefinitized Project Agreement No. 1, dated April 23, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on August 5, 2021)
- Advance Purchase Agreement, dated May 5, 2021, between Novavax, Inc. and the Gavi Alliance (Filed With SEC on August 5, 2021)
- Amendment Number 1 to the iPDP and Budget of the Outbreak Response Funding Agreement (Step 2), entered into on November 2, 2020, between Novavax, Inc. and the Coalition for... (Filed With SEC on March 1, 2021)
- Amendment of Solicitation/Modification of Contract, Modification No. 3, entered into January 5, 2021, between the Company and the U.S. Department of Defense Joint Program... (Filed With SEC on March 1, 2021)
- Amendment of Solicitation/Modification of Contract, Modification No. 2, entered into December 1, 2020, between the Company and the U.S. Department of Defense Joint Program... (Filed With SEC on March 1, 2021)
- Modification No. 06 to Undefinitized Project Agreement No. 01, entered into January 19, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
- Modification No. 05 to Undefinitized Project Agreement No. 01, dated January 12, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
